Literature DB >> 35707155

Ibogaine and Their Analogs as Therapeutics for Neurological and Psychiatric Disorders.

Robert B Kargbo1.   

Abstract

Entities:  

Year:  2022        PMID： 35707155      PMCID： PMC9190277          DOI： 10.1021/acsmedchemlett.2c00214

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  6 in total

Review 1.  Cardiovascular and temperature adverse actions of stimulants.

Authors:  James R Docherty; Hadeel A Alsufyani
Journal:  Br J Pharmacol       Date:  2021-05-06       Impact factor: 8.739

2.  Psychedelics without hallucinations?

Authors:  Robert F Service
Journal:  Science       Date:  2022-01-27       Impact factor: 47.728

Review 3.  Meta-Analysis: Efficacy and Tolerability of Vesicular Monoamine Transporter Type 2 Inhibitors in the Treatment of Tic Disorders.

Authors:  Emily Behling; Luis C Farhat; Angeli Landeros-Weisenberger; Michael H Bloch
Journal:  Mov Disord       Date:  2022-02-22       Impact factor: 10.338

Review 4.  The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020).

Authors:  Genís Ona; Juliana Mendes Rocha; José Carlos Bouso; Jaime E C Hallak; Tre Borràs; Maria Teresa Colomina; Rafael G Dos Santos
Journal:  Psychopharmacology (Berl)       Date:  2021-08-18       Impact factor: 4.530

Review 5.  Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity.

Authors:  David E Olson
Journal:  Biochemistry       Date:  2022-01-21       Impact factor: 3.162

Review 6.  Clinical development of valbenazine for tics associated with Tourette syndrome.

Authors:  Robert H Farber; Angel Angelov; Kristine Kim; Tara Carmack; Dao Thai-Cuarto; Eiry Roberts
Journal:  Expert Rev Neurother       Date:  2021-04-01       Impact factor: 4.618
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.